Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
At present, treatment options for osimertinib resistance are very limited. Dual inhibition of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) significantly improved the progression-free survival (PFS) of advanced EGFR-mutant non–small cell lung cancer (NSCLC...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2022-01-01
|
| Colección: | Frontiers in Pharmacology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fphar.2021.746707/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|